Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Guardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date
  • News

Guardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date

  • The Pharma Data
  • March 4, 2025

Guardian Pharmacy Services Reports Preliminary Q4 and Full-Year 2024 Results, Provides 2025 Guidance Guardian Pharmacy Services, Inc. (“Guardian” or the “Company”) (NYSE: GRDN), one of the largest long-term care (LTC)…

Read MoreGuardian Pharmacy Services Reports Q4 & Full-Year 2024 Results, 2025 Outlook & Earnings Call Date
Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®
  • Regulatory

Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®

  • The Pharma Data
  • March 4, 2025

Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra®…

Read MoreCelltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra®
  • Research

QIAGEN Files Legal Action to Protect QuantiFERON IP in TB Testing

  • The Pharma Data
  • March 3, 2025

QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint…

Read MoreQIAGEN Files Legal Action to Protect QuantiFERON IP in TB Testing
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings
  • Business

SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings

  • The Pharma Data
  • March 1, 2025

SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This…

Read MoreSmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
  • Business

Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio

  • The Pharma Data
  • March 1, 2025

Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio Demetra Holding, a pioneering and independent international medical device company specializing in anti-infective cements, spacers, and biomaterials for orthopedic…

Read MoreDemetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer
  • News

Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth

  • The Pharma Data
  • March 1, 2025

Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth Wedgewood, the nation’s largest provider of compounded veterinary medications and pharmacy solutions, has appointed Jessica Knopp-Gwynne as Chief Revenue…

Read MoreWedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth
Incyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting
  • Press Releases

Incyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting

  • The Pharma Data
  • March 1, 2025

Incyte (Nasdaq: INCY) has announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7–11, 2025, in Orlando, where the company will present multiple…

Read MoreIncyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day
  • News

Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

  • The Pharma Data
  • March 1, 2025

Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day Arrowhead Pharmaceuticals Expands “We’ll Get There Soon” Campaign with New Resources for Familial Chylomicronemia Syndrome on Rare Disease Day Arrowhead…

Read MoreArrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day
  • Press Releases

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program

  • The Pharma Data
  • March 1, 2025

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications…

Read MoreSarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program
CHMP Recommends EU Approval of ENHERTU® for HER2 LowUltralow Metastatic Breast Cancer
  • Regulatory

CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer

  • The Pharma Data
  • March 1, 2025

CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have achieved a significant milestone with the recommendation for approval…

Read MoreCHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases
  • Research

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases

  • The Pharma Data
  • March 1, 2025

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin…

Read MoreSeismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases
  • Press Releases

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies

  • The Pharma Data
  • March 1, 2025

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS…

Read MoreBridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates
  • Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona
  • Heart Failure 2026 Data Highlight Vutrisiran’s Strong Benefits Across ATTR-CM Patient Groups
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.